Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Paraproteinemias 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Leukemia, B-Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hematologic Diseases 1Bronchiolitis Obliterans Syndrome 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 71fludarabine phosphate 63Busulfan 47Peripheral Blood Stem Cell Transplantation 44Tacrolimus 41Mycophenolic Acid 37Antilymphocyte Serum 37Filgrastim 32Cyclosporine 30Melphalan 29Whole-Body Irradiation 28Radiotherapy 28fludarabine 26Methotrexate 23Methylprednisolone 18Etoposide 18Cord Blood Stem Cell Transplantation 17Rituximab 13Alemtuzumab 13Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 10Sirolimus 9Thiotepa 8Cytarabine 8sargramostim 7Prednisone 7Epoetin Alfa 7Flow Cytometry 6thymoglobulin 5Trimethoprim, Sulfamethoxazole Drug Combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Hsp90 inhibitor KU757 × Plasma cell × Clear all
NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Kyowa Kirin Co., Ltd.

Phase 1/2 Completed
95 enrolled 13 charts
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡